Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06335667 · ClinicalTrials.gov registry record · NA
mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer
A NA study of Muscle-invasive Bladder Cancer and Urothelial Bladder Cancer, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06335667: Recruiting NA study of Muscle-invasive Bladder Cancer and Urothelial Bladder Cancer, sponsored by University of California, Irvine.
NCT06335667 is a NA study of Muscle-invasive Bladder Cancer and Urothelial Bladder Cancer that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 30 participants, below the 1,333-participant average among 10 other Muscle-invasive Bladder Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06335667, a NA study of Muscle-invasive Bladder Cancer and Urothelial Bladder Cancer, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot, single arm, prospective study that aims to validate the accuracy of the VI-RADS score obtained via multi-parametric magnetic resonance imaging (mpMRI) compared to pathologic cancer stage obtained via diagnostic transurethral bladder tumor resection (TURBT) as well as compare the clinical and quality of life outcomes between these diagnostic modalities in patients with suspected muscle-invasive bladder cancer (MIBC).
Primary Outcome
VI-RADS is a five-point scoring system developed to standardize imaging and reporting of bladder tumor invasiveness on mpMRI. It predicts the degree of possible muscular propria invasion ("muscle-invasiveness") of bladder tumors. Once diagnostic TURBT is performed, the VI-RADS score from mpMRI will be compared to the pathologic tumor (T) stage from a diagnostic TURBT to assess for concordance.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST mpMRI + Diagnostic TURBT
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-03-27 |
| Est. Completion | 2030-04 |
| Phase | NA |
What NCT06335667 shows while recruiting
NCT06335667 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,333-participant average among 10 other Muscle-invasive Bladder Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Muscle-invasive Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which mpMRI + Diagnostic TURBT is the first listed.
NCT06335667 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06335667 about?
NCT06335667 is a clinical study titled "mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer". This is a pilot, single arm, prospective study that aims to validate the accuracy of the VI-RADS score obtained via multi-parametric magnetic resonance imaging (mpMRI) compared to pathologic cancer stage obtained via diagnostic transurethral bladder tumor resection (TURBT) as well as compare the cli...
What is the current status of trial NCT06335667?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-03-27. Estimated completion is 2030-04.
What conditions does trial NCT06335667 study?
This clinical trial studies the following conditions: Muscle-invasive Bladder Cancer, Urothelial Bladder Cancer.
What interventions are being tested in trial NCT06335667?
The interventions under investigation include: mpMRI + Diagnostic TURBT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06335667?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06335667 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle-invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06335667's enrollment target sits among peer trials
30 10th of 10 higher than 1 of 10 other Muscle-invasive Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Muscle-invasive Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
RECRUITING · Phase 2
-
Sample Collection for Ongoing Research and Product Evaluation Study
RECRUITING
-
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
ACTIVE NOT RECRUITING · Phase 3
-
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
ACTIVE NOT RECRUITING · Phase 3
-
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI